The Latest Breaking News from Tylenol

Kimberly-Clark to acquire Kenvue, owner of Tylenol, in a £40 billion deal amid controversy over the painkiller's safety concerns and declining sales.

Kleenex maker’s deal for troubled Johnson & Johnson spinoff comes amid lawsuits and regulatory scrutiny

Kenvue stock is down 28% in 2025 amid controversy surrounding its Tylenol brand, which is linked to autism when used during pregnancy.

Amid a contentious political environment, consumer pharmaceutical firm Kenvue Inc (NYSE:KVUE) finds itself under a harsh spotlight. Specifically, its popular drug Tylenol has attracted the ire of the White House. Late last month, President Donald Trump stated on Truth Social that pregnant women shouldn't use Tylenol unless absolutely necessary. With…

Promotion of unproven claims from President Trump and RFK Jr. linking acetaminophen (Tylenol) to autism have significantly impacted Kenvue’s business.

A 2017 post by Tylenol on X (formerly Twitter) highlighted by White House has fueled a buzz around President Donald Trump‘s claim that the drug is linked with autism in kids.

Trump was eager to single out drug manufacturer despite no new evidence to support administration’s unproven claims

Kenvue stock is trailing the broader markets by a wide margin in 2025 due to regulatory concerns over its flagship Tylenol product.

Late-night hosts celebrate the return of Kimmel and recap Trump’s ‘insane’ press conference baselessly blaming Tylenol for autism